GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Price-to-Owner-Earnings

Homology Medicines (STU:35H) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines Price-to-Owner-Earnings?

As of today (2024-06-08), Homology Medicines's share price is €14.85. Homology Medicines does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Homology Medicines's Price-to-Owner-Earnings or its related term are showing as below:


STU:35H's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), Homology Medicines's share price is €14.85. Homology Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-32.61. Therefore, Homology Medicines's PE Ratio for today is At Loss.

As of today (2024-06-08), Homology Medicines's share price is €14.85. Homology Medicines's EPS without NRI for the trailing twelve months (TTM) ended in was €-32.41. Therefore, Homology Medicines's PE Ratio without NRI for today is At Loss.

During the past 8 years, Homology Medicines's highest PE Ratio without NRI was 4.45. The lowest was 0.00. And the median was 3.12.


Homology Medicines Price-to-Owner-Earnings Historical Data

The historical data trend for Homology Medicines's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Price-to-Owner-Earnings Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Homology Medicines's Price-to-Owner-Earnings

For the Biotechnology subindustry, Homology Medicines's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Homology Medicines's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Price-to-Owner-Earnings falls into.



Homology Medicines Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Homology Medicines's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=14.85/-617.04
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Homology Medicines  (STU:35H) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Homology Medicines Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (STU:35H) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines